Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of EZN-2208 (PEG-SN38) With or Without Cetuximab in Metastatic Colorectal Carcinoma
2009-014876-23Phase 2Completed
- Sponsor
- Enzon Pharmaceuticals
- Start
- Dec 2009
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of firtecan pegol in colorectal cancer (CRC) (3 arms), sponsored by Enzon Pharmaceuticals. Primary endpoint: Overall response rate. Started Dec 2009; status: completed.
02
Drugs
firtecan pegol
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2009-014876-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014876-23.